What is it? Why is it important?

Researchers have an ethical obligation to make their study results public, whether they are positive, negative or inconclusive.

As a minimum, study results should be published in a registry recognized by the World Health Organization (WHO) (e.g. ClinicalTrials.gov), including where else the study was initially registered. By registering study results, the SP-INV fulfils scientific, ethical, and regulatory obligations (e.g. results are submitted to the Ethics Committee (EC) and RA (e.g. Swissmedic) via a Clinical Study report), within 1 year after study completion.

 

A study registry has many advantages as it:

  • Functions as a public record where study results are presented in a standardized format
  • Complies with required ethical obligations towards study participants
  • Ensures that research results contribute to overall medical knowledge
  • Reduced publication and outcome reporting biases
  • Facilitates systematic reviews and other research literature reviews

What do I need to do?

As SP-INV:

  • Update any selected internationally recognised public registries
  • Make an attempt to publish your research results in a scientific peer-reviewed journal, making findings more easily available to the scientific community
  • Include experts able to support you with the write-up of a scientific publication (e.g. statistician, medical reviewer)
  • With the aim to further medical research, grant data access to all those who may benefit from your study results, (e.g. with or without proven benefit)
  • Adhere to publication agreements defined at study start (e.g. selection of publication partner(s), contribution and authorship, adherence to publication guidelines such as the ICMJE)
  • Consider the prospect of informing study participants and/or their community about your study results
  • Ensure that for all publications, measures are taken to maintain the confidentiality of study participants

Where can I get help?

Your local CTU can support you with experienced staff regarding this topic

External Links

Swissethics – see in particular

  • RAPS Registry, a database of all projects approved by the ethics committees in Switzerland

Swiss and international registries:

References

Declaration of Helsinki – see in particular principle

  • 36 Registration and Publication and Dissemination of results

SAMS Research with human subjects – see in particular chapter

  • Chapter 11 Publication of study results

CIOMS guideline – see in particular

  • 24 Public accountability for health-related research

ICMJE – see in particular

  • Clinical trials recommendation

Swiss Law

 

HRA – see in particular article

  • Art. 56 Registration

ClinO – see in particular articles

  • Art. 64 - 67 Registration

ClinO-MD – see in particular articles

  • Art. 41 Registration
Abbreviations
  • CIOMS - Council for International. Organizations of Medical Sciences
  • ClinO – Clinical Trials Ordinance
  • ClinO-MD – Ordinance on Clinical Trials with Medical Devices
  • CTU – Clinical Trials Unit
  • EC – Ethics Committee
  • EudraCT – European Union Drug Regulating Authorities Clinical Trials Database
  • CTU – Clinical Trials Unit
  • HRA – Human Research Act
  • ICMJE – International Committee of Medical Journal Editors
  • KOFAM – Coordination Portal for Human Research
  • RAPS – Registry of all Projects in Switzerland
  • SAMS – Swiss Academy of Medical Sciences
  • SP-INV – Sponsor Investigator
  • RA – Regulatory Authorities
  • WHO – World Health Organization
Completion ↦ Ethics and Laws ↦ Publications ↦ Responsibilities
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Basic Drug or Device
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Statistics
Completion Drug or Device
Current Path (click to copy): Completion ↦ Ethics and Laws ↦ Publications ↦ Responsibilities

Please note: the Easy-GCS tool is currently under construction.